Latest News

PharmaTech Outlook Selects GenPro to be Among 2017's Top 10 Solution Providers to Biopharma Discovery and Development Organizations


Back

GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients.

The work will be presented in a poster session on Sunday, December 4, 2016, 6:00 PM-8:00 PM. The project is titled, "Epigenetic Profiling in High-Risk MDS and AML Patients Identifies Pre-Treatment Methylation Patterns That Indicate Response to Hypomethylating Agents: A Pilot Study (Absttract #2885)." It is scheduled for Session #617 - Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis, at the San Diego Convention Center, Hall GH. The lead author on the study who will be presenting is Dr. Chetasi Talati from the Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, FL. A poster summarizing this presentation is available at: ASH 2016 Poster.